Postdoctoral Researchers

Dr. Pramod Darvin

Dr. Pramod Darvin

Postdoctoral Researcher
Dr. Pramod Darvin received his Master of Science in Biochemistry and Postgraduate Diploma in Bioinformatics from Bharatidasan University, India. In 2007 he received his Master of Technology in Biotechnology from Sathyabama University, India. He obtained his Ph.D. in Medicine, Tumor biology in 2014 from Konkuk University, South Korea. His Ph.D. work involved the study of the modulation of Jak/STAT pathway in breast and colon cancer with special attention to STAT1, 3 and 5b. He also explored the impact of STAT1 tyrosine and serine phosphorylation in the transcriptional level changes of its downstream genes and cell fate determination. He was a Postdoctoral researcher (2014 – 2016) and teaching assistant at the Department of Pathology, Konkuk University School of Medicine, South Korea. He then joined the Cancer Research Program at the Bio-innovation Centre of Rajiv Gandhi Centre for Biotechnology, India as a Postdoctoral Researcher (2016 – 2018). He did the preclinical evaluation and cellular and molecular events accompanied by photodynamic therapy employing genetically encoded molecular probes. He has recently joined QBRI under the supervision of Dr. Eyad Elkord.
Dr. Pramod’s research interests involve the crosstalk of tumor microenvironment and intratumoral heterogeneity in epithelial to mesenchymal transitions in breast and colon cancers. He also focuses on the epigenetic changes in chromatin remodeling during the EMT process, to bring out effective therapeutic switches to regulate the transition process.
A Chandrasekharan, S Varadarajan, A Lekshmi, S Lupitha, M Nair, P Darvin, L Chandrasekhar, P Pillai, S Thankayyan; MR Pillai, (2018) A High-Throughput real-time in vitro assay using mitochondrial targeted roGFP for screening of drugs targeting mitochondria. (Submitted).

HJ Byun, P Darvin, DY Kang, N Sp, YH Joung, JH Park, SJ Kim, YM Yang (2017) Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells. Oncol rep. 37 (6), 3270-3278.

Darvin P, Joung YH, Kang DY, Nipin SP, Byun HJ, et al., (2017) Tannic acid inhibits EGFR/STAT1/3 and enhances p38/STAT1 signaling axis in breast cancer cells. J Cell mol Med. 21 (4), 720-734.

Joung YH, Darvin P, Kang DY, Nipin SP, Byun HJ, et al., (2016) Methylsulfonylmethane inhibits RANKL-induced osteoclastogenesis in BMMs by suppressing NFkB and STAT3 activities. PLoS ONE. 11(7): e0159891.

Kim DN, Joung YH, Darvin P, Kang DY, Nipin SP, et al., (2016) Methylsulfonylmethane enhances BMP-2 induced osteoblast differentiation in mesenchymal stem cells. Mol. Med. Rep. 14: 460 – 466.

Kang DY, Darvin P, Yoo YB, Joung YH, Nipin SP, Byun HJ, Yang YM, (2016) Methylsulfonylmethane inhibits Her2 expression through STAT5b in breast cancer cells. Int. J. Oncol 48: 836 – 842.

Darvin P, Baeg SJ, Joung YH, Nipin SP, Kang DY, et al., (2015) Tannic acid inhibits the Jak2/STAT3 pathway and induces G1/S arrest and mitochondrial apoptosis in YD-38 gingival cancer cells. Int. J. Oncol 47: 1111 – 1120.
Back to Top